3902 logo

Medical Data Vision
3902

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
¥63.90B
EV
¥62.22B
Shares Outstanding
37.86M
Beta
1.21
Industry
Medical - Healthcare Information Services

Wall Street View

Analyst Rating
HOLD
Analyst Target Price
Number of Analysts
2
P/E 2025E
237.75x
P/Revenue 2025E
9.30x

Historical 3Y Growth Rate

Revenue
EPS
Operating Cash Flow
Free Cash Flow

Forecasted 3Y Growth Rate

Revenue
EPS
Operating Cash Flow
Free Cash Flow

Margins & Returns

Gross Margin 2025E
73.03%
Net Profit Margin 2025E
3.93%
ROE 2025E
8.70%
ROCE 2024
-21.52%

Dividends

DPS 2025E
¥9.00
Payout Ratio 2025E
126.76%
Div. Yield 2025E
0.53%
DPS Last 3Y CAGR

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Medical Data Vision Co., Ltd.

gainify
3902 logo

Medical Data Vision Co., Ltd.

3902

Medical Data Vision Co., Ltd., together with its subsidiaries, develops, produces, maintains, and sells medical information integration systems in Japan, Europe, North America, Asia, and Oceania. The company offers data network services; data utilization services; MDV...

Sector

Healthcare

Industry

Medical - Healthcare Information Services

CEO

Iwasaki, Hiroyuki

Employees

315

IPO Date

2014-12-16

Headquarters

Sumitomo Fudosan Kanda Building, 10th Floor, 7 Kanda Mitoshirocho, Chiyoda, Tokyo, 101-0053, Japan

📊 Stock Price & Performance

The last closing price of Medical Data Vision (3902) is ¥1688.00, reflecting a -0.06% change from the prior session. Last updated: January 1, 2026 at 1:34 AM Eastern Time

Review the recent 3902 stock performance trends:Past 1 Month: Medical Data Vision (3902) shares have +246.61%.Past 3 Months: The stock has +185.62%.Past 6 Months: 3902 shares have +316.79%. Last updated: January 1, 2026 at 12:13 AM Eastern Time

Over the last year, Medical Data Vision (3902) has established a 52-week price range between a high of ¥1693.00 and a low of ¥332.00. This metric is essential for assessing the stock's annual volatility. Last updated: January 1, 2026 at 12:13 AM Eastern Time

Medical Data Vision (3902) is considered a medium volatility stock. It has a beta of 1.21, which means it typically moves 1.21 times as much as the broader market. Over the past 52 weeks, 3902 has traded within a ¥332.00 – ¥1693.00 range. Last updated: January 1, 2026 at 12:13 AM Eastern Time

Based on current 3902 analyst forecasts and market assumptions, the consensus price target for Medical Data Vision (3902) is ¥425.00 for 2027. Relative to the current price of ¥1688.00, this implies a potential downside of -74.82%. Price targets reflect forward-looking estimates based on information available at the time and are inherently subject to change as underlying assumptions, company fundamentals, or market conditions evolve. Last updated: January 1, 2026 at 1:34 AM Eastern Time

A ¥1,000 investment in Medical Data Vision 5 years ago, when the stock was trading around ¥3029.69, would be worth approximately ¥557.15 today, based solely on share price performance (excluding dividends). This represents a total return of -44.28% over the period, equivalent to a compound annual growth rate (CAGR) of -11.04%. Past performance reflects historical price movements only and does not imply future results. Last updated: January 1, 2026 at 12:13 AM Eastern Time

💰 Financial Metrics & Reports

The current Medical Data Vision (3902) market capitalization is approximately ¥63.90B, based on its latest share price and shares outstanding. Market capitalization represents the total market value of a company's equity and is calculated by multiplying the current stock price by the number of shares outstanding. As a result, Medical Data Vision's market cap fluctuates with changes in its share price and share count. Last updated: January 1, 2026 at 12:13 AM Eastern Time

In the most recently reported quarter, Medical Data Vision (3902) generated ¥1.62B in revenue, representing a +20.15% year over year change. For the next quarter, analyst consensus currently expects revenue of approximately ¥2.22B, implying an expected +24.87% year over year change. Quarterly revenue results and expectations reflect underlying demand trends, pricing dynamics, product or service mix, seasonality, and broader macroeconomic conditions. Actual results may differ from consensus estimates as new information becomes available. Last updated: January 1, 2026 at 4:07 AM Eastern Time

In the most recently reported fiscal year, Medical Data Vision (3902) generated net income of ¥-0.79B, compared with ¥979.00M in the prior fiscal year, representing a -180.80% year over year change. For the upcoming fiscal year, analyst consensus currently estimates net income of ¥270.00M. Net income may be positive or negative and can fluctuate materially from year to year due to changes in operating performance, non-recurring or one-time items, accounting treatments, capital structure, and broader macroeconomic conditions. Last updated: January 1, 2026 at 4:07 AM Eastern Time

According to its latest quarterly filing, Medical Data Vision (3902) reported EBITDA of ¥182.18M, representing a -227.62% year over year change. EBITDA is a non-GAAP measure and does not account for depreciation, amortization, interest expense, taxes, or capital expenditures. As a result, it should be considered alongside other financial metrics when assessing operating performance. Actual results may differ from estimates as company-specific or macroeconomic conditions evolve. Last updated: January 1, 2026 at 4:07 AM Eastern Time

Based on the latest available data, Medical Data Vision (3902) is currently trading at a last twelve months (LTM) P/E ratio of -152.43x. The P/E ratio reflects how much investors are willing to pay today for a dollar of earnings and can vary meaningfully over time due to changes in profitability, growth expectations, margin outlook, and earnings volatility. Last updated: January 1, 2026 at 4:07 AM Eastern Time

📅 Earnings & Dividends

In the most recently reported quarter, Medical Data Vision (3902) revenue was ¥1.62B, compared with analyst consensus expectations of ¥1.60B, representing a +1.10% revenue surprise versus expectations. Earnings per share (EPS) for the quarter were ¥1.73. Revenue and EPS surprises may be positive or negative and can influence near-term stock performance depending on expectations, forward guidance, and broader market and sector conditions. For a detailed history of analyst expectations versus reported results, view the full estimates vs. actuals track record here: 👉 Estimates vs. Actuals Last updated: January 1, 2026 at 4:07 AM Eastern Time

📈 Analyst Information

Analyst assessments of whether Medical Data Vision (3902) consensus price target is overvalued or undervalued are generally expressed relative to consensus valuation frameworks and price targets, rather than as an absolute judgment.Current share price: ¥1688.00Consensus price target: ¥425.00Implied return: -74.82% An implied return above current levels indicates that, on average, analysts view the stock as trading below their estimated fair value. Conversely, an implied return below current levels suggests the stock may be fully valued or priced above consensus expectations. This content is for informational purposes only and does not constitute investment advice. Last updated: January 1, 2026 at 4:07 AM Eastern Time

Based on the latest available analyst coverage, Medical Data Vision (3902) currently carries a Hold consensus rating. Analysts' average 3902 price target is ¥425.00. Relative to the current share price of ¥1688.00, this suggests a potential price change of approximately -74.82%. Analyst views are forward-looking estimates and should not be considered investment advice. Last updated: January 1, 2026 at 4:07 AM Eastern Time

Like other publicly traded stocks, Medical Data Vision (3902) shares are bought and sold on stock exchanges such as TSE and other supported markets, depending on the listing. The most common way to buy shares is through an online brokerage account. To get started, you typically need to: Open an account with a licensed stock brokerComplete the broker's verification processFund your accountPlace a buy order for Medical Data Vision (3902) shares Trading involves risk, and investors should consider their financial objectives and risk tolerance before investing.

ℹ️ Company Information

At the top right of this page, you'll see a star icon labeled Add to watchlist. Click it to add 3902 to your watchlist.

Medical Data Vision trades under the ticker symbol 3902 on the TSE stock exchange. The ticker 3902 is used to identify the company's common stock across trading platforms, market data providers, and regulatory filings.

As of the most recently reported period, Medical Data Vision (3902) employs approximately 315 people worldwide. Reported employee figures may fluctuate over time due to hiring activity, restructuring, automation initiatives, or changes in business strategy. Headcount data is typically disclosed in company filings and reflects full-time employees unless otherwise stated. Last updated: January 1, 2026 at 12:13 AM Eastern Time

Medical Data Vision (3902) operates in a highly competitive market with companies that often have different business models, geographic exposure, and end markets. While no two companies are identical, the following firms are generally considered the closest Medical Data Vision (3902) stock peers based on overlapping products, services, and competitive dynamics:Yarward Electronics (Shandong) (301337)Suzhou MedicalSystem Technology (603990)FINDEX (3649)eWeLL (5038)JMDC (4483)Goodwill E-Health Info (688246)GENOVA (9341)BrainAurora Medical Technology (6681) These peers may differ in size, business mix, financial profile, and strategic focus, but they are commonly referenced due to overlapping markets, customer segments, or competitive positioning relative to Medical Data Vision.

gainifypowered-by-sp
Socials
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on TrustpilotFollow us on YouTubeFind us on Google Maps

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2026 Gainify. All rights reserved.